of IL-10 and transforming growth factor-β compared with vehicle treatment (p < 0.05), which was consistent with Western blot results. Conclusions: Transplantation of autologous BMMNCs delays the development of atherosclerosis, most probably via the attenuation of inflammatory responses, which could be a new approach for treating carotid atherosclerosis.
Introduction
Atherosclerosis (AS) leads to cardiovascular disease which gives rise to fatal clinical outcomes, such as stroke or myocardial infarction [1] . The atherosclerotic lesion derives from the declination of the number of endothelial progenitor cells (EPCs) or its function [2, 3] followed by lipid accumulation in macrophages and vascular smooth muscle cells (VSMCs) [4] .
Inflammation is the central event at all stages of AS. Circulating immune cells are involved in the atherosclerotic process through the secretion of a large number of cytokines [5] . They can be classified into proinflammatory and anti-inflammatory cytokines [5, 6] . The former is characterized with IL-6 and CD147 [5] [6] [7] . IL-6 can pro-mote T lymphocyte differentiation and the production of inflammatory mediators including TNF-α and IL-1β [5, 6] . CD147 is an inducer of extracellular matrix metalloproteinases (MMPs), including MMP-9 [7] . The upregulation of MMP-9 is a direct cause of the development and rupture of atherosclerotic plaques [5] . The latter primarily consists of IL-10 and transforming growth factor (TGF)-β [5, [8] [9] [10] . IL-10 is a prototypic anti-inflammatory cytokine, which can inhibit the activation of macrophages, activity of MMP-9, release of proinflammatory cytokines and expression of cyclooxygenase-2 in lipidloaded and activated macrophage foam cells [8, 10] . TGF-β can reduce T cell infiltration and increase collagen production in the plaques [9, 10] . Therefore, maintenance of the balance of proinflammatory and anti-inflammatory mediators is recognized as an ideal approach for suppressing the development of AS.
The therapeutic use of bone marrow mononuclear cells (BMMNCs) for ischemic diseases is currently under clinical investigation [11] [12] [13] . Given secretion of IL-10 and TGF-β, BMMNCs have been shown to exhibit protective effects on myocardial infarction and cerebral infarction by regulation of proinflammatory and anti-inflammatory cytokines [14, 15] . However, there is no consensus on the role of BMMNCs in the development of AS [16] [17] [18] . One study showed that intracoronary injection of unfractionated BMMNCs in patients with acute STelevation myocardial infarction does not accelerate AS progression [16] . In contrast, 2 other studies reported that BMMNCs promote atherosclerotic plaque development in diabetic apoE -/-mice [17] and wild-type mice [18] . On analysis of those studies [16, 18] we found that the BMMNCs used were collected from syngeneic mice instead of autologous animals. In this study, we established an atherosclerotic plaque model in the carotid artery of rabbits by air desiccation. We aimed to investigate the effects of autologous BMMNCs on the area of atherosclerotic plaques and explore the underlying mechanisms.
Materials and Methods

Carotid Injury and Treatment
New Zealand white rabbits (male, 1.5-1.7 kg, n = 78) were purchased from the Animal Experimental Center of Zhengzhou University. All protocols were approved by the Animal Care and Use Committee of Zhengzhou University and were in accordance with the institutional guidelines. These animals were divided into 4 groups. In the naive group (n = 6) rabbits received a conventional diet for 10 weeks and were not subjected to any operations. In the sham operated group (n = 24) the middle of the neck of these rabbits was incised and then sutured; the animals were fed a high-cholesterol diet for 10 weeks. In the vehicle treatment group (n = 24) rabbits were subjected to air desiccation and were given a high-cholesterol diet for 8 weeks; they were then treated with 1 ml of phosphate-buffered saline (PBS) at the end of the eighth week and were fed a high-cholesterol diet for the next 2 weeks. Finally, the BMMNC treatment group (n = 24) consisted of rabbits that were subjected to air desiccation and fed a high-cholesterol diet for 8 weeks; they were then intravenously treated with 1 × 10 7 BMMNCs at the end of the eighth week and were given a high-cholesterol diet for next 2 weeks. These rabbits were sacrificed on 1, 3, 7, and 14 days after BMMNCs treatment.
The atherosclerotic plaque model was established as previously described [19] . In brief, rabbits were anesthetized by intramuscular injection of 0.2 ml/kg of xylazine hydrochloride. The left common carotid arteries of the rabbits were surgically exposed and temporarily occluded using two microvascular clamps with a 3-cm interval. The endothelia of the arterial lumen were dried by nitrogen air flow for 8 min at 80 ml/min via needle puncture. After desiccation, the clamps were removed to restore blood flow and the cuts were sutured. The rabbits were fed the diets previously described.
Bone Marrow Cell Processing
Experimental animals underwent bone marrow puncture 8 weeks after carotid artery injury. The rabbits were fastened to the work table after being anaesthetized through xylazine hydrochloride injection. The puncture point was located in the tibial medial, 1 cm under the anterior tibialis tuberosity. The bone marrow aspirates were washed in PBS and centrifuged (3,000 rpm, 10 min). They were then added to an equal amount of Ficoll-Paque Plus (Tianjin TBD Ltd., Beijing, China) and centrifuged at 2,500 rpm for 30 min. The white film was extracted and washed 3 times in PBS. A total of 5 ml of DMEM containing 10 μl of penicillin-streptomycin solution, 100 μl of bovine serum albumin and 50 μl of bromodeoxyuridine (BrdU) solution (final concentration 12 g/ml; Sigma-Aldrich, St. Louis, Mo., USA) was added to the cell precipitation and medium. After incubating overnight at 37 ° C, the BMMNCs were collected and filtered through a 500 mesh strainer (diameter = 25 μm), washed with PBS and counted using a hemocytometer. Finally, 1 × 10 7 cells labeled with BrdU were intravenously injected via the ear vein. Vehicle-treated animals were injected with an equal volume of PBS.
Vessel Harvesting
The carotid arteries were fixed in 4% paraformaldehyde for 12 h at 4 ° C, then embedded in Tissue-Tek OCT compound (Sakura Finetechnical, Tokyo, Japan), snap-frozen, and stored at -80 ° C. Samples were sectioned at a thickness of 5 μm and placed on poly-L -lysine-coated slides for immunofluorescent and hematoxylin-eosin (HE) staining.
Assessment of AS
The extent of AS was quantified by calculating the lesion size in the carotid artery [20] .
Ultrasonography
The carotid arteries of rabbits fed a high-cholesterol or conventional diet for 8 or 10 weeks were examined using a Siemens Se-quoia 512 ultrasound scanner with a 6-to 14-MHz linear probe (Siemens, Mountain View, Calif., USA). The average plaque diameter was measured.
Immunofluorescence Double Staining
Vessel specimens from rabbits on days 1 and 14 after transplantation were cut into 5-μm sections and then treated with 2 M HCl for 30 min and washed before incubating with blocking buffer. Endogenous peroxidase was blocked with 3% hydrogen peroxide for 5 min, and nonspecific binding was blocked in blocking buffer (5% normal goat serum, 0.3% Triton X in PBS) for 1 h at room temperature. Sheep anti-BrdU polyclonal antibody (1: 100; Abcam, Cambridge, Mass., USA) and mouse anti-rabbit monoclonal antibody against CD31 (1: 100; Abcam) were used as primary antibodies. Sections were incubated in the primary antibodies overnight at 4 ° C and then with Alexa Fluor 488-conjugated donkey anti-sheep IgG H+L antibody (1: 800; Abcam) and CFL594-conjugated donkey anti-mouse IgG (1: 200; Santa Cruz Biotechnology, Santa Cruz, Calif., USA) for 2 h at room temperature for visualization of antibody binding. Photomicrographs were obtained with an epifluorescence deconvolution microscope (Olympus CKX41, Olympus, Japan). Cells positive for BrdU were counted as BMMNC-derived cells.
RT-PCR
RNA was isolated (Beijing ComWin Biotech, Beijing, China) and analyzed by RT-PCR. Each PCR assay was performed in duplicate using cDNA samples isolated from individual rabbits (n = 6 per group). The primers used for amplification were as follows. For IL-6, the forward primer was 5 ′ -TGAGACCTGCCTGCTGA-GA-3 ′ , and the reverse primer was 5 ′ -TGAGGGTGGCTTC-TTCATTC-3 ′ (product band, 185 bp). For IL-10, the forward primer was 5 ′ -GAGAACCACAGTCCAGCCAT-3 ′ , and the reverse primer was 5 ′ -CATGGCTTTGTAGACGCCTT-3 ′ (product band, 179 bp). For CD147, the forward primer was 5 ′ -CAGAA-TGACAAAGGCAAGAACG-3 ′ , and the reverse primer was 5 ′ -GGCTTGGGAGTGACTTGAGG-3 ′ (product band, 269 bp). For TGF-β, the forward primer was 5 ′ -CCGCAACAACACCCA-CA-3 ′ , and the reverse primer was 5 ′ -CGGCACCTCATCAT-CACTT-3 ′ (product band, 112 bp). For GAPDH, the forward primer was 5 ′ -GAACGGGAAACTCACTGGCAT-3 ′ , and the reverse primer was 5 ′ -CCTTCTTGATGTCGTCATACTTAGC-3 ′ (product band, 110 bp). Twenty-microliter mixtures were electrophoresed in 1.5% agarose gel. Values were normalized to the GAP-DH band by Quantity One software.
Western Blot
Vessels homogenized in radioimmunoprecipitation assay (RIPA) lysis buffer (Boster, Wuhan, China) were clarified by centrifugation (14,000 rpm, 5 min, 4 ° C). A standard Western blotting protocol was followed. The samples were separated by 4% stacking gel and 10% separating gel was transferred onto polyvinylidene fluoride membranes (Millipore, Billerica, Mass., USA). The membranes were blocked for 1 h at room temperature or overnight at 4 ° C with 5% nonfat milk (Sangon Biotech, Shanghai, China). They were then incubated for 2 h at room temperature or overnight at 4 ° C with the following primary antibodies: rabbit anti-rabbit CD147 (1: 400; Bioss, Beijing, China), cavia anti-rabbit IL-6 (1: 400; Uscn Life science Inc., Wuhan, China), mouse anti-rabbit IL-10 (1: 500; Global Biotech, Shanghai, China), rabbit anti-rabbit TGF-β1-1: 500; Global Biotech), mouse anti-rabbit β-Actin (1: 500; Boster). After 3 washes, membranes were incubated with horseradish peroxidase-conjugated secondary antibodies as follows: goat anti-rabbit (1: 1,000, Boster), goat anti-guinea pig (1: 1,000, Global Biotech), goat anti-mouse (1: 1,000, Boster) for 1 h at room temperature. Protein bands were visualized by enhanced chemiluminescence with an ECL Plus chemiluminescence detection kit (Sangon Biotech). The optical density of the protein bands was quantified by Gel Analysis v2.02 software (Clinx Science Instruments).
Statistical Analysis
All data were analyzed by SPSS 17.0 statistical software and presented as the mean ± standard deviation (SD). Fisher's exact test was used to examine differences in mortality among the 4 groups and sizes of the atherosclerotic plaques. Analysis of variance (ANOVA) was used to determine differences in body weights between the groups. Differences among multiple groups were assessed with one-way ANOVA followed by the least significant difference test for serum lipids and expression of IL-6, IL-10, CD147, and TGF-β. Values of p < 0.05 were considered statistically significant.
Results
Transplantation of BMMNCs Did Not Affect Rabbit Mortality
At the end of each protocol, the mortalities of the 4 groups were 0 (0/6), 0 (0/6), 1 (1/24) and 0 (0/24), respectively. No significant differences were observed among the groups (p > 0.05). The single rabbit died within the first 24 h after air desiccation.
BMMNCs Treatment Did Not Affect the Level of Serum Lipid and Body Weight
Exposure to a high-cholesterol diet for 8 weeks resulted in a significant increase in the body weights of rabbits in the sham operated, vehicle and BMMNC-treated groups compared to those in the naive group (naive: 2.01 ± 0.27; sham: 2.78 ± 0.54; vehicle: 2.81 ± 0.38; BMMNC: 2.86 ± 0.41; p < 0.05). However, no differences were observed between the 3 groups fed a high-cholesterol diet (p > 0.05). Two weeks after vehicle or BMMNC treatment, the rabbits that received a high-cholesterol diet had a significantly increased body weight compared to those in the naive group (naive: 2.33 ± 0.31; sham: 3.68 ± 0.54; vehicle: 3.85 ± 0.66; BMMNC: 3.94 ± 0.52; p > 0.05). BMMNC treatment did not increase the body weight of rabbits compared to vehicle treatment.
The serum levels of TC, TG, HDL and LDL in the sham operated and vehicle animals were significantly elevated compared with those in the naive group at 8, 9, or 10 weeks after a high-cholesterol diet. BMMNC treatment did not reduce the levels of TC, TG, HDL, and LDL compared to vehicle treatment at these observed time points ( fig. 1 a-d ; p > 0.05).
BMMNCs Reduced the Carotid Atherosclerotic Plaque Area
Using an ultrasonographic imaging method, we found that the walls of carotid arteries in the naive and sham groups were smooth and no clear ultrasonographic plaque was found in these rabbits after 10 weeks of a highcholesterol diet ( fig. 2 a, b) . In contrast, the carotid artery walls of rabbits in the vehicle and BMMNC groups were rough with visible hyperechoic plaques ( fig. 2 c, d ). In addition, the average plaque diameter in the vehicle-treated group was significantly more than that in the BMMNC treatment group ( fig. 2 c-i) . Representative vessels taken from comparable regions of the carotid from naive-, sham-, vehicle-and BMMNC-treated rabbits were stained with HE ( fig. 2 e-h ). We found that autologous BMMNC transplantation significantly reduced areas of atherosclerotic plaque compared to the vehicle treatment group (n = 6 per group, p < 0.05; fig. 2 j) . Moreover, BrdU-positive cells were found in the plaques of carotid arteries of BMMNC-treated rabbits on days 1 and 14 after the injection of cells ( fig. 3 b, c) . The number of BrdU-positive cells were (19.1 ± 3.5/mm 2 ) and persisted at high levels for at least 14 days (30.1 ± 4.1/mm 2 ; n = 6 per time point, day 14 vs. day 1, p < 0.05; fig. 3 d) . 
BMMNCs Treatment Reduced the Expression of Proinflammatory Mediators IL-6 and CD147 but Increased the Expression of Anti-Inflammatory Cytokines IL-10 and TGF-β
Given that inflammation plays a key role in the process of AS [5] , the proinflammatory mediators IL-6 and CD147 were examined. Using RT-PCR, we found that autologous BMMNC transplantation significantly reduced the expression of IL-6 compared to that in the vehicle treatment group on day 1 after the injection of cells (p < 0.05). IL-6 in carotid atherosclerotic plaque reached the lowest levels on day 3 and persisted at low values for at least 14 days after cell transplantation. Similarly, the levels of CD147 in rabbits of the BMMNC transplantation group were significantly reduced on day 3 compared to that in the vehicle treatment group, and reached the lowest on day 7 and persisted at low values for at least 14 days after BMMNC treatment (p < 0.05). Conversely, the levels of IL-10 and TGF-β in rabbits of the BMMNC transplantation group were significantly increased compared to those in the vehicle treatment group on day 1 and persisted at high values for at least 14 days after BMMNC treatment (n = 6 per time point, p < 0.05 vs. the corresponding vehicle group; fig. 4 a-e) . Moreover, Western blot analysis showed similar expression patterns of IL-6, IL-10, TGF-β, and CD147 to those found in RT-PCR (n = 6 per time point, p < 0.05 vs. the corresponding vehicle group; fig. 4 f, g ). 
Discussion
Our research confirmed that transplanted autologous BMMNCs can migrate into atherosclerotic plaques in carotid arteries. Administered BMMNCs reduced the area of atherosclerotic plaques. The underlying mechanism involves the upregulation of anti-inflammatory cytokines (IL-10 and TGF-β) and the downregulation of proinflammatory mediators (IL-6 and CD147). Autologous BMMNC transplantation may represent a new therapeutic approach for treating AS.
Stromal cell-derived factor 1 (SDF-1) is expressed by VSMCs, endothelial cells and macrophages in atherosclerotic arteries [21] . Bone marrow contains a highly mobile population of CXCR4+ cells [22] . Through the CXCR4-SDF-1 signaling pathway, BMMNCs can migrate into atherosclerotic lesions and have many vital effects on the progression of AS.
IL-6 has been identified in the atherosclerotic lesion and its expression level has a significantly positive relationship with the extent and size of the plaques [23, 24] . Overexpression of IL-6 may trigger a variety of immune responses and enhance fatty lesion development, leading to the aggravation of AS [25, 26] . Furthermore, IL-6 is independently associated with the extent of AS in patients and can predict the future of coronary artery disease [27, 28] . CD147, expressed on many cell types, is the central inducer of MMP-9 derived from monocytes, which plays a key role in plaque rupture, resulting in myocardial infarction or stroke [7] . In our study, the content of CD147 and IL-6 was significantly decreased by autologous BMMNC treatment. This result indicates that autologous BMMNC transplantation can suppress AS development by a reduction of proinflammatory mediators.
IL-10 is a pleiotropic cytokine which has a protective role in both atherogenesis and plaque instability [8] . It can be secreted by monocyte and Th2 subtype lymphocytes. Its prototypic role is to inhibit the activation of macrophages and subsequent secretion of MMPs and other inflammatory mediators, such as tumor necrosis factor-α, monocyte chemotactic protein-1 and intracellular adhesion molecule-1 [8] . Moreover, it can alter the lipid metabolism in macrophages and prevent the formation of foam cells [8] . TGF-β plays a major role in the regulation of inflammation and immune responses by regulating macrophages or T cells [9] . Upregulation of TGF-β not only reduces the formation of atherosclerotic plaque, but also induces a transition from a macrophagerich unstable plaque phenotype to a more stable, fibrous lesion [9, 29] . In addition, TGF-β plays an important role in maintaining the normal structure of the vessel wall via inhibiting VSMC proliferation, migration, and the differentiation of VSMCs [10] . In our experiment, the IL-10 and TGF-β content in rabbits of the autologous BMMNC Most previous studies used allogeneic or syngeneic cells to explore the effects of BMMNCs on AS [16, 18, 31] . Indeed, transplantation of autologous BMMNCs may have different effects on recipients compared to allogeneic or syngeneic treatment [32, 33] . Firstly, allogeneic or syngeneic BMMNCs are not harvested from the recipient analysis of IL-6, IL-10, eNOS, and TGF-β on days 1, 3, 7, and 14 after BMMNC injection. b-e Quantification analysis of RT-PCR bands showed BMMNC treatment reduced the expression of IL-6 and CD147 but increased the production of IL-10 and TGF-β. g-j Western blot results were consistent with the RT-PCR assay. * p < 0.05 versus corresponding vehicle groups, n = 6 per group. and immunologic rejections may be present to some degree [32, 33] , and may produce inflammatory cytokines and accelerate the process of AS. In contrast, immunologic rejections do not occur in the process of transplantation of autologous cells [34] . Secondly, autologous BMMNCs are obtained after AS, the compositions of BMMNCs may change and tend to have anti-inflammatory properties, similar to the effects of stroke on bone marrow [35, 36] . Together, our data support the belief that the transplantation of autologous BMMNCs may have protective effects against AS.
